Expression of DNA repair proteins MSH2, MLH1 and MGMT in human benign and malignant thyroid lesions: An immunohistochemical study

Medical Science Monitor

Volumn 17, Issue 3, 2011, Pages 4-

  Giaginis, Constantinos ^a   Michailidi, Christina ^a   Stolakis, Vasileios ^a   Alexandrou, Paraskevi ^a   Tsourouflis, Gerasimos ^a   Klijanienko, Jerzy ^b   Delladetsima, Ioanna ^a   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b INSTITUT CURIE   (France)

Author keywords

Clinicopathological parameters; Diagnosis; DNA repair proteins; Immunohistochemistry; Thyroid malignancy

Indexed keywords

KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN MLH1; PROTEIN MSH2;

ADULT; ANAPLASTIC CARCINOMA; ARTICLE; BENIGN TUMOR; BLOOD VESSEL; CANCER INVASION; CANCER SIZE; DOWN REGULATION; FEMALE; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHATIC SYSTEM; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PROTEIN EXPRESSION; THYROID FOLLICULAR CARCINOMA; THYROID HYPERPLASIA; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROID TUMOR;

EID: 79952389795     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/msm.881444     Document Type: Article

References (56)

1. Leenhardt L, Grosclaude P, Cherie-Challine L: Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid, 2004; 14: 1056-60
2. Jemal A, Siegel R, Ward E et al: Cancer statistics, 2009, CA. Cancer J Clin, 2009; 59: 225-49
3. Davies L, Welch HG: Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA, 2006; 295: 2164-67
4. Ward EM, Jemal A, Chen A: Increasing incidence of thyroid cancer: is diagnostic scrutiny the sole explanation? Future Oncol, 2010; 6: 185-88
5. Hundahl SA, Fleming ID, Fremgen AM, Menck HR: A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer, 1998; 83: 2638-48
6. Segev DL, Umbricht C, Zeiger MA: Molecular pathogenesis of thyroid cancer. Surg Oncol, 2003; 12: 69-90
7. Gharib H, Papini E: Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am, 2007; 36: 707-35
8. Stang MT, Carty SE: Recent developments in predicting thyroid malignancy. Curr Opin Oncol, 2009; 21: 11-17
9. Fischer S, Asa L: Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med, 2008; 132: 359-72
10. Besic N, Sesek M, Peric B et al: Predictive factors of carcinoma in 327 patients with follicular neoplasm of the thyroid. Med Sci Monit, 2008; 14(9): CR459-67
11. Vriens MR, Schreinemakers JM, Suh I et al: Diagnostic markers and prognostic factors in thyroid cancer. Future Oncol, 2009; 5: 1283-93
12. Golbidi S, Laher I: Antioxidant therapy in human endocrine disorders. Med Sci Monit, 2010; 16(1): RA9-24
13. Friedberg EC, McDaniel LD, Schultz RA: The role of endogenous and exogenous DNA damage and mutagenesis. Curr Opin Genet Dev, 2004; 14: 5-10
14. Jackson SP, Bartek J: The DNA-damage response in human biology and disease. Nature, 2009; 461: 1071-78
15. Peterson CL, Côté J: Cellular machineries for chromosomal DNA repair. Genes Dev, 2004; 18: 602-16
16. Muniandy PA, Liu J, Majumdar A et al: DNA interstrand crosslink repair in mammalian cells: step by step. Crit Rev Biochem Mol Biol, 2010; 45: 23-49
17. Gatzidou E, Michailidi C, Tseleni-Balafouta S, Theocharis S: An epitome of DNA repair related genes and mechanisms in thyroid carcinoma. Cancer Lett, 2010; 290: 139-47
18. Liu K, Huang H, Mukunyadzi P et al: Promoter hypermethylation: An important epigenetic mechanism for hMLH1 gene inactivation in head and neck squamous cell carcinoma. Otolaryngology, 2002; 126: 548-53
19. Demokan S, Suoglu Y, Demir D et al: Microsatellite instability and methylation of the DNA mismatch repair genes in head and neck cancer. Ann Oncol, 2006; 17: 995-99
20. Ruschenburg I, Vollheim B, Stachura J et al: Analysis of DNA mismatch repair gene expression and mutations in thyroid tumours. Anticancer Res, 2006; 26: 2107-12
21. Guan H, Ji M, Hou P et al: Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. Cancer, 2008; 113: 247-55
22. Hsieh P: Molecular mechanisms of DNA mismatch repair. Mut Res, 2001; 486: 71-87
23. Marti TM, Kunz C, Fleck O: DNA mismatch repair and mutation avoidance pathways. J Cell Physiol, 2002; 191: 28-41
24. Haydon AM, Jass JA: Emerging pathways in colorectal cancer development. Lancet Oncol, 2002; 3: 83-88
25. Schagdarsurengin U, Gimm O, Dralle H et al: Island methylation of tumor- related promoters occurs preferentially in undifferentiated carcinoma. Thyroid, 2006; 16: 633-42
26. Ishida E, Nakamura M, Shimada K et al: DNA hypermethylation status of multiple genes in papillary thyroid carcinomas. Pathobiology, 2007; 74: 344-52
27. Hoeijmakers JH: Genome maintenance mechanisms for preventing cancer. Nature, 2001; 411: 366-74
28. Matsukura S, Miyazaki K, Yakushiji H et al: Expression and prognostic significance of O6-methylguanine-DNA methyltransferase in hepatocellular, gastric, and breast cancers. Ann Surg Oncol, 2001; 8: 807-16
29. Kohya N, Miyazaki K, Matsukura S et al: Deficient expression of O(6)- methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. Ann Surg Oncol, 2002; 9: 371-79
30. Matsukura S, Miyazaki K, Yakushiji H et al: Combined loss of expression of O6-methylguanine-DNA methyltransferase and hMLH1 accelerates progression of hepatocellular carcinoma. J Surg Oncol, 2003; 82: 194-200
31. Sawhney M, Rohatgi N, Kaur J et al: MGMT expression in oral precancerous and cancerous lesions: correlation with progression, nodal metastasis and poor prognosis. Oral Oncol, 2007; 43: 515-22
32. Cooper WA, Kohonen-Corish MRJ, Chan C et al: Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in nonsmall- cell lung cancer and precursor lesions. Histopathology, 2008; 52: 613-22
33. Rosai J: Appendix C. Staging of cancer. In: Houston M (ed.) Rosai and Ackerman's Surgical Pathology, 9th edn. Mosby, London, 2004; 2809-10
34. Michailidi C, Theocharis S, Stolakis V et al: Expression and methylation profile of DNA repair genes in Greek colon adenocarcinoma patients. Virchows Archiv, 2009; 455: 88
35. Giaginis C, Tsourouflis G, Zizi-Serbetzoglou A et al: Clinical Significance of Ephrin (Eph)-A1, -A2, -A4, -A5 and -A7 Receptors in Pancreatic Ductal Adenocarcinoma. Pathol Oncol Res, 2010; 16(2): 267-76
36. Giaginis C, Zarros A, Alexandrou P et al: Evaluation of coxsackievirus and adenovirus receptor expression in human benign and malignant thyroid lesions. APMIS, 2010; 118: 210-21
37. Mar KC, Eimoto T, Tateyama H et al: Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions. Histopathology, 2006; 48: 286-94
38. Melck A, Masoudi H, Griffith OL et al: Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer. Ann Surg Oncol, 2007; 14: 3403-11
39. Wiseman SM, Griffith OL, Melck A et al: Evaluation of type 1 growth factor receptor family expression in benign and malignant thyroid lesions. Am J Surg, 2008; 195: 667-73
40. Mitmaker E, Alvarado C, Bégin LR, Trifiro M: Microsatellite Instability in Benign and Malignant Thyroid Neoplasms. J Surg Res, 2008; 150: 40-48
41. Soares P, dos Santos NR, Seruca R et al: Benign and malignant thyroid lesions show instability in microsatellite loci. Eur J Cancer, 1997; 33: 293-96
42. Lazzereschi D, Palmirotta R, Ranieri A et al: Microsatellite instability in thyroid tumors and tumor-like lesions. Br J Cancer, 1999; 79: 340-45
43. Vaish M, Mishra SK, Mandhami A et al: Assessment of microsatellite instability in bladder and thyroid malignancies. Teratog Carcinog Mutagen, 2003; Suppl.1: 255-65
44. Vaish M, Mishra A, Kaushal M et al: Microsatellite instability and its correlation with clinicopathological features in a series of thyroid tumors prevalent in iodine deficient areas. Exp Mol Med, 2004; 36: 122-29
45. Shia J: Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. the utility of immunohistochemistry. J Mol Diagn, 2008; 10: 293-300
46. Tachibana KE, Gonzalez MA, Coleman N: Cell-cycle-dependent regulation of DNA replication and its relevance to cancer pathology. J Pathol, 2005; 205: 123-29
47. Giaginis C, Vgenopoulou S, Vielh P, Theocharis S: MCM proteins as diagnostic and prognostic markers in the clinical setting. Histol Histopathol, 2010; 25: 351-70
48. Okayasu I, Saegusa M, Fujiwara M et al: Enhanced cellular proliferative activity and cell death in chronic thyroiditis and thyroid papillary carcinoma. J Cancer Res Clin Oncol, 1995; 121: 746-52
49. Berends MJW, Hollema H, Wu Y et al: MLH1 and MSH2 protein expression as a pre-screening marker in hereditary and non-hereditary endometrial hyperplasia and cancer. Int J Cancer, 2001; 92: 398-403
50. Felton KE, Gilchrist DM, Andrew SE: Constitutive deficiency in DNA mismatch repair. Clin Genet, 2007; 71: 483-98
51. Shia J, Ellis NA, Klimstra DS: The utility of immunohistochemical detection of DNA mismatch repair gene proteins. Virchows Arch, 2004; 445: 431-41
52. Staebler A, Laf SF, Hedrick Ellenson L: Altered expression of hMLH1 and hMSH2 protein in endometrial carcinomas with microsatellite instability. Hum Pathol, 2000; 31: 354-58
53. Arif S, Blanes A, Diaz-Cano SJ: Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma. Histopathology, 2002; 41: 357-62
54. Kang DY, Kim KH, Kim JM et al: High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean population. Thyroid, 2007; 17: 1031-38
55. Kitajima Y, Miyazaki K, Matsukura S et al: Loss of expression of DNA repair enzymes MGMT, hMLH1 and hMSH2 during tumor progression in gastric cancer. Gastric Cancer, 2003; 6: 86-95
56. Soejima H, Zhao W, Mukai T: Epigenetic silencing of the MGMT gene in cancer. Biochem Cell Biol, 2005; 83: 429-37